Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ANTX

ANTX - AN2 Therapeutics, Inc. Stock Price, Fair Value and News

2.80USD-0.05 (-1.75%)Delayed

Market Summary

ANTX
USD2.80-0.05
Delayed
-1.75%

ANTX Stock Price

View Fullscreen

ANTX RSI Chart

ANTX Valuation

Market Cap

83.5M

Price/Earnings (Trailing)

-1.26

Price/Sales (Trailing)

50.78

Price/Free Cashflow

-1.41

ANTX Price/Sales (Trailing)

ANTX Profitability

Return on Equity

-59.7%

Return on Assets

-54.45%

Free Cashflow Yield

-70.98%

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

ANTX Earnings

Earnings (TTM)

-66.0M

Earnings Growth (Yr)

-8.44%

Earnings Growth (Qtr)

1.66%

Breaking Down ANTX Revenue

Last 7 days

8.5%

Last 30 days

40%

Last 90 days

13.4%

Trailing 12 Months

-63.9%

How does ANTX drawdown profile look like?

ANTX Financial Health

Current Ratio

8.28

ANTX Investor Care

Shares Dilution (1Y)

53.55%

Diluted EPS (TTM)

-2.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202294.0K307.0K748.0K1.4M
202100069.0K

Tracking the Latest Insider Buys and Sells of AN2 Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 10, 2024
eizen joshua m
acquired
-
-
60,000
chief legal officer
Mar 15, 2024
eizen joshua m
acquired
-
-
30,000
chief legal officer
Mar 15, 2024
krause kevin michael
acquired
-
-
30,000
chief strategy officer
Mar 15, 2024
eckburg paul
acquired
-
-
30,000
chief medical officer
Mar 15, 2024
day lucy
acquired
-
-
27,500
chief financial officer
Mar 15, 2024
easom eric
acquired
-
-
99,000
chief executive officer
Mar 15, 2024
chanda sanjay
acquired
-
-
27,500
chief development officer

1–10 of 50

Which funds bought or sold ANTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
JANE STREET GROUP, LLC
reduced
-0.47
-1,025,740
192,290
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
new
-
30,066
30,066
-%
May 15, 2024
RA CAPITAL MANAGEMENT, L.P.
unchanged
-
-95,704,300
18,041,700
0.23%
May 15, 2024
Nantahala Capital Management, LLC
reduced
-80.21
-9,855,030
319,404
0.02%
May 15, 2024
MORGAN STANLEY
added
25.01
-54,719
13,533
-%
May 15, 2024
OCCUDO QUANTITATIVE STRATEGIES LP
new
-
122,515
122,515
0.02%
May 15, 2024
Atom Investors LP
new
-
38,691
38,691
-%
May 15, 2024
Man Group plc
sold off
-100
-375,725
-
-%
May 15, 2024
683 Capital Management, LLC
sold off
-100
-274,402
-
-%
May 15, 2024
TCG Crossover Management, LLC
reduced
-41.93
-49,822,400
5,054,130
0.40%

1–10 of 50

Are Funds Buying or Selling ANTX?

Are funds buying ANTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANTX
No. of Funds

Unveiling AN2 Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 03, 2024
octagon capital advisors lp
10.1%
3,009,927
SC 13G
Apr 10, 2024
frazier life sciences public fund, l.p.
2.4%
707,879
SC 13G
Feb 14, 2024
pfizer inc
4.58%
1,362,499
SC 13G/A
Feb 14, 2024
citadel advisors llc
5.2%
6
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
18.7%
5,551,295
SC 13G/A
Feb 13, 2024
easom eric
5.2%
1,572,170
SC 13G
Feb 12, 2024
janus henderson group plc
4.3%
1,279,975
SC 13G/A
Feb 09, 2024
adjuvant global health technology fund, l.p.
7.0%
2,080,051
SC 13G/A
Feb 09, 2024
tcg crossover gp i, llc
9.0%
2,678,209
SC 13G/A
Jul 25, 2023
tcg crossover gp i, llc
6.6%
1,289,320
SC 13G

Recent SEC filings of AN2 Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jul 12, 2024
4
Insider Trading
Jul 03, 2024
SC 13G
Major Ownership Report
Jun 24, 2024
8-K
Current Report
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading

Peers (Alternatives to AN2 Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

AN2 Therapeutics, Inc. News

Latest updates
Simply Wall St04 Jul 202407:00 am
TradingView2 months ago
Insider Monkey4 months ago

AN2 Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue35.2%63046622827.0027.0025.0015.002.00
Operating Expenses6.0%12,47611,77010,3337,6837,5946,9324,9982,050
  S&GA Expenses11.4%3,7243,3423,6352,0501,7821,587898401
  R&D Expenses17.8%8,7527,4286,6985,6335,3125,3453,8501,649
Net Income-4.4%-11,842-11,339-10,120-7,655-7,545-6,943-5,007-2,048
Net Income Margin38.1%-30.32*-49.01*-105.09*-288.83*-312.22*---
Free Cashflow19.5%-7,638-9,487-9,595-6,742-8,993-4,691-5,257-1,543
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets-12.6%12113915499.0091.0010311012012165.00
  Current Assets5.3%11611112698.0090.0099.0010711712060.00
    Cash Equivalents57.9%25.0016.0033.0041.0027.0027.0029.0041.0083.0012.00
Liabilities-24.1%11.0014.0015.0011.009.007.004.004.005.003.00
  Current Liabilities-100.0%-14.0015.0011.009.007.004.004.005.003.00
Shareholder's Equity-11.3%11112513988.0083.0095.00106116115-
  Retained Earnings-10.8%-171-154-137-120-105-89.72-77.88-66.54-56.42-47.38
  Additional Paid-In Capital1.0%282279277209188185184183172-
Shares Outstanding0.1%30.0030.0030.0022.0019.0019.0014.0011.003.003.00
Float----109---119--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Cashflow From Operations-3.1%-17,593-17,068-11,800-12,824-11,596-7,638-9,487-9,595-6,742-8,993-4,691-5,257-1,543
  Share Based Compensation6.9%2,3852,2322,1691,9432,0681,4721,2281,2424494333541798.00
Cashflow From Investing6159.5%26,290420-62,4627,87710,8876,055-2,317-39,48613,977----
Cashflow From Financing208.7%349-32166,06619,050199--10.007,17863,187-969-240-79,744
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ANTX Income Statement

2024-03-31
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 14,655$ 11,985
General and administrative3,6414,054
Total operating expenses18,29616,039
Loss from operations(18,296)(16,039)
Other income, net1,679716
Net loss attributable to common stockholders$ (16,617)$ (15,323)
Net loss per share attributable to common stockholders, basic$ (0.56)$ (0.79)
Net loss per share attributable to common stockholders, diluted$ (0.56)$ (0.79)
Weighted-average number of shares used in computing net loss per share, basic29,763,27819,385,646
Weighted-average number of shares used in computing net loss per share, diluted29,763,27819,385,646
Other comprehensive loss:  
Unrealized (loss) gain on investments$ (222)$ 199
Comprehensive loss$ (16,839)$ (15,124)

ANTX Balance Sheet

2024-03-31
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 24,693$ 15,647
Short-term investments89,51791,648
Prepaid expenses and other current assets2,1033,212
Total current assets116,313110,507
Long-term investments3,90427,194
Other assets, long-term1,0431,043
Total assets121,260138,744
Current liabilities:  
Accounts payable2,4332,676
Accrued compensation9954,018
Accrued liabilities6,9146,681
Other current liabilities321668
Total liabilities10,66314,043
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 29,815,663 and 29,741,445 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital281,616278,881
Accumulated other comprehensive gain53275
Accumulated deficit(171,072)(154,455)
Total stockholders' equity110,597124,701
Total liabilities and stockholders' equity$ 121,260$ 138,744
ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEan2therapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES35

AN2 Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for AN2 Therapeutics, Inc.? What does ANTX stand for in stocks?

ANTX is the stock ticker symbol of AN2 Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AN2 Therapeutics, Inc. (ANTX)?

As of Fri Jul 19 2024, market cap of AN2 Therapeutics, Inc. is 83.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers. The fair value of AN2 Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AN2 Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AN2 Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANTX is over valued or under valued. Whether AN2 Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact AN2 Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANTX.

What is AN2 Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, ANTX's PE ratio (Price to Earnings) is -1.26 and Price to Sales (PS) ratio is 50.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANTX PE ratio will change depending on the future growth rate expectations of investors.